2MD, Banaz State Hospital, Uşak, Turkey
3MD, Uşak Training and Research Hospital, Uşak, Turkey DOI : 10.37845/ret.vit.2021.30.64 Purpose: In the study we aimed to investigate effect of concomitant epiretinal membrane on results of anti-VEGF treatment in diabetic macular edema.
Materials and Methods: In the study we included patients with epiretinal membrane and diabetic macular edema who were followed in the retina unit. Patients received initial loading doses of three injections; followed by 0.5 mg/month ranibizumab injections as needed. In all patients, central macular thickness, optical coherence tomography fi ndings and best-corrected visual acuity were evaluated.
RESULTS: The study included 31 eyes of 37 patients (4 patients received bilateral treatment). The mean age of the patients was 62.4±7.4 years. The patients received an average of 3.9 doses of ranibizumab injection. In the study, 12 (38%) of 31 eyes underwent cataract surgery. The mean central macular thickness (CMT) was 429.25±127.41?m at baseline and 324.42±69.74 at the end of treatment (p< 0.01). The mean BCVA (logMAR) was determined as 0.64±0.34 at baseline and 0.50±0.27 after the treatment (p< 0.01). No signifi cant differences were found in the CMT and BCVA between genders (p> 0.05).
Conclusion: It was found that anti-VEGF (ranibizumab) treatment provided signifi cant improvement on CMT and BCVA (logMAR) values in cases with diabetic macular edema and epiretinal membrane.
Keywords : Epiretinal membrane, macular edema, anti-VEGF